Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from complications from cancer treatment to nutritional disorders and diseases brought on by viral infections and immune malfunction.
Disease targets include large patient populations with inflammatory bowel diseases (ulcerative colitis and Crohn’s), digestive disorders (exocrine pancreatic insufficiency in cystic fibrosis patients), and the COVID-19 pandemic (acute and long-haul COVID-related GI infections).
IN THE NEWS
|
Sep 14 ,2021
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
|
|
Sep 13 ,2021
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
|
|
Sep 10 ,2021
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
|
